A review of the efficacy and tolerability of agomelatine in the treatment of major depression

Expert Opinion on Investigational Drugs

Volumn 16, Issue 12, 2007, Pages 1999-2004

  Ghosh, Anita ^a   Hellewell, Jonathan S E ^a  

^a TRAFFORD GENERAL HOSPITAL   (United Kingdom)

Author keywords

5 HT2c antagonists; 5 HT2c serotonin receptors; Agomelatine; Antidepressant; Depression; Major depression; Major depressive disorder; Mechanism of action; MT1 melatonin receptors; MT2 melatonin receptors; MT2 receptor agonist; New antidepressants

Indexed keywords

AGOMELATINE; ANTIDEPRESSANT AGENT; FLUOXETINE; IMIPRAMINE; PAROXETINE; PLACEBO; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE; ACETAMIDE DERIVATIVE; MELATONIN;

CLINICAL TRIAL; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HUMAN; INFLUENZA; LONG TERM CARE; MAJOR DEPRESSION; NONHUMAN; RELAPSE; REMISSION; REVIEW; RHINOPHARYNGITIS; SEXUAL DYSFUNCTION; SLEEP; TRANQUILIZING ACTIVITY; UNSPECIFIED SIDE EFFECT; ANIMAL; DRUG POTENTIATION; METABOLISM; PSYCHOLOGICAL ASPECT;

ACETAMIDES; ANIMALS; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, MAJOR; HUMANS; MELATONIN;

EID: 39549112360     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.12.1999     Document Type: Review

References (21)

1. WORLD HEALTH ORGANIZATION: The world health report 2001 - Mental Health: New Understanding, New Hope. World Health Organization, Geneva, Switzerland (2001).
2. AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Menial Disorders, 4th Edition. Washington, DC: American Psychiatric Press (1994).
3. KESSLER RC, BERGLUND P, DEMLER O, JIN R, MERIKANGAS KR, WALTERS EE: Lifetime Prevalence and age-of-onset distributions of DSM-IV disorders in the National comorbidity survey replication. Arch. Gen. Psychiatry (2005) 62:593-602.
4. ESEMED/MHEDEA 2000 INVESTIGATORS: Prevalence of mental disorders in Europe: results from the European study of the epidemiology of mental disorders (ESEMeD) project. Acta PSychiatry (2004) 109(Suppl. 420):21-27.
5. PANDI-PERUMAL SR, SRINIVASAN V, CARDINALI DP, MONTI JM: Could agomelatine be the ideal antidepressant? Expert Rev. Neurother. (2007) 7(2):1595-1608.
6. YOUS S, ANDRIEUX J, HOWELL HE et al.: Novel naphthalenic ligands with high affinity for the melatonin receptor. J. Med. Cbem. (1992) 35:1481-1485.
7. MILLAN MJ, GOBERT A, LEJEUNE F et al.: The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J. Pharmacol. Exp. Ther. (2003) 306:954-964.
8. LOO H, HALE A, D'HAENEN H: Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int. Clin. Psychopharmacol. (2002) 17:239-247.
9. HAMILTON M: Development of a rating scale for primary depressive illness. Br. J. Soc. Clin. Pychol. (1967) 6:278-296.
10. MONTGOMERY SA, ASBERG M: A new depression scale designed to be sensitive to change. Br. J. Psychiatry (1979) 134:382-389.
11. HAMILTON M: The assessment of anxiety states by rating. Br. J. Pychol. (1959) 32:50-55.
12. GUY W. ECDEU Assessment Manual for Pychopharmacology. US Department of Health, Education, and Welfare publication (ADM) Government Printing Office, Washington, DC, USA (1976):223-244.
13. KENNEDY SH, EMSLEY R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur. Neuropsychopharm. (2006) 16:93-100.
14. 2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int. J. Neuropsychopharm. (2007) 10:661-673.
15. MONTGOMERY SA, KASPER S: Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int. Clin. Psychopharm. (2007) 22:283-291.
16. MONTGOMERY SA, KENNEDY SH, BURROWS GD, LEJOYEUX M, HINDMARCH 1: Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomised double-blind, placebo-controlled discontinuation study. Int. Clin. Psychopharm. (2004) 19:271-280.
17. KENNEDY SH: Sexual function in remitted depressed patients following agomelatine and venlafaxine XR treatment. Eur. Neuropsychopharm. (2005) 15:(Suppl. 3):S440.
18. GUILLEMINAULT C: Efficacy of agomelatine versus venlafaxine on subjective steep of patients with major depressive disorder. Eur Neuropsychopharm. (2005) 15:(Suppl. 3):S419.
19. QUERA SALVA MA, VANIER B, CHAPOTOT F et al.: Effect of agomelatine on the sleep EEG in patients with major depressive disorder. Eur Neuropsychopharm. (2005) 15:(Suppl. 3):S435.
20. GOODWIN GM, ROUILLON F, EMSLEY R: Long term efficacy of agomelatine, a novel antidepressant, in the prevention of relapse in out-patients with major depressive disorder. Eur. Neuropsychopharm. (2007) 17:(Suppl. 4):S361.
21. KHAN A, KOLTS RL, THASE ME, RANGA RAMA KRISHNAN K, BROWN W: Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. Am. J. Psychiatry (2004) 16(11)2045-2049.